Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.
Read the position paper: Rare primary liver cancers: An EASL position paper
Faculty: Thomas Berg (Moderator), Ruben de Kleine (Faculty), Henning Wege (Faculty)
Related episodes:
- S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond
- S5E13: Basics in decision-making for liver cancer treatment
- S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance